Efficacy and safety of guanfacine extended-release in the treatment of attention-deficit/hyperactivity disorder in adults: Results of a randomized, double-blind, placebo-controlled study
This study was sought to investigate guanfacine extended-release (GXR) efficacy and safety in adults with attention-deficit/hyperactivity disorder (ADHD). Researchers designed a phase 3, double-blind, placebo-controlled study (conducted between October 2016 and July 2017) including Japanese patients aged ≥ 18 years with ADHD (DSM-5).
Other Articles in this Edition
Four Lessons We’ve Learned from Moving Online
Helpful at-home school resources for kids with learning and attention difficulties
Study Looks at Everyday Experiences of ADHDers Over 50
ADHD and Screen Time During the Quarantine
Nourishing Nutrition: ADHD and Nutrition — Is There a Link?
For those with ADHD, social distancing presents both major challenges and opportunities
What Is ‘Time Blindness’ and Do You Have It?
Meta-analysis reveals shared genetic factors between childhood psychopathology, adult depression